Should IDEAYA’s DLL3 Combo Trial and Early IDE849 Signals Prompt a Rethink From IDYA Investors?

Simply Wall St.04-04

IDEAYA Biosciences recently reported first-patient-in for a global Phase 1 trial combining IDE849, a DLL3-targeting Topo-I ADC, with its PARG inhibitor IDE161 in DLL3-upregulated solid tumors such as ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624660937?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-04 07:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624660937","market":"hk","top_or_hot":-1,"title":"Should IDEAYA’s DLL3 Combo Trial and Early IDE849 Signals Prompt a Rethink From IDYA Investors?","media":"Simply Wall St.","content":"<div>\n<p>IDEAYA Biosciences recently reported first-patient-in for a global Phase 1 trial combining IDE849, a DLL3-targeting Topo-I ADC, with its PARG inhibitor IDE161 in DLL3-upregulated solid tumors such as ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/should-ideayas-dll3-combo-trial-and-early-ide849-signals-pro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should IDEAYA’s DLL3 Combo Trial and Early IDE849 Signals Prompt a Rethink From IDYA Investors?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould IDEAYA’s DLL3 Combo Trial and Early IDE849 Signals Prompt a Rethink From IDYA Investors?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-04 07:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/should-ideayas-dll3-combo-trial-and-early-ide849-signals-pro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IDEAYA Biosciences recently reported first-patient-in for a global Phase 1 trial combining IDE849, a DLL3-targeting Topo-I ADC, with its PARG inhibitor IDE161 in DLL3-upregulated solid tumors such as ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/should-ideayas-dll3-combo-trial-and-early-ide849-signals-pro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AI","symbol_name":"C3.ai, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/should-ideayas-dll3-combo-trial-and-early-ide849-signals-pro","article_id":"2624660937","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/should-ideayas-dll3-combo-trial-and-early-ide849-signals-pro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624660937","pubTimestamp":1775258112,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IDEAYA Biosciences recently reported first-patient-in for a global Phase 1 trial combining IDE849, a DLL3-targeting Topo-I ADC, with its PARG inhibitor IDE161 in DLL3-upregulated solid tumors such as small cell lung cancer, neuroendocrine tumors, and melanoma.\nAn interesting aspect is the early Phase 1 signal of multiple partial responses for IDE849, including in small cell lung cancer patients previously treated with IMDELLTRA®, highlighting the potential of this mechanistically distinct...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AI":"C3.ai, Inc.","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","ISBC":"投资者银行","BK4543":"AI","AIPO":"Defiance AI and Power Infrastructure ETF","BK4551":"寇图资本持仓","IDYA":"IDEAYA Biosciences","BK4211":"区域性银行","BK4587":"ChatGPT概念","AGIX":"通用人工智能 ETF-AGIX","BK4528":"SaaS概念","BK4588":"碎股","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4585":"ETF&股票定投概念","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4023":"应用软件","BK4139":"生物科技"},"translate_title":"IDEAYA的DLL3组合试验和早期IDE849信号是否应该促使Ideya投资者重新思考？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1.5,"AIPO":0.73,"ISBC":1.5,"AGIX":0.62,"AI":0.62,"CHAT":0.62,"AIYY":0.6,"ARTY":0.62},"content_text":"IDEAYA Biosciences recently reported first-patient-in for a global Phase 1 trial combining IDE849, a DLL3-targeting Topo-I ADC, with its PARG inhibitor IDE161 in DLL3-upregulated solid tumors such as small cell lung cancer, neuroendocrine tumors, and melanoma. An interesting aspect is the early Phase 1 signal of multiple partial responses for IDE849, including in small cell lung cancer patients previously treated with IMDELLTRA®, highlighting the potential of this mechanistically distinct ADC and PARG inhibitor pairing. With early combination data and IDE849’s emerging response profile in pretreated small cell lung cancer, we’ll assess how this development reshapes IDEAYA’s investment narrative. This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.AdvertisementWhat Is IDEAYA Biosciences' Investment Narrative?For IDEAYA to make sense as a holding, you have to believe in its platform-style approach to precision oncology rather than any single asset. The new IDE849/IDE161 first-patient-in update reinforces that idea: it nudges IDE849 and PARG inhibition closer to the front of the story and broadens the near-term catalyst set beyond darovasertib’s OptimUM-02 data. In the short term, the combination trial and IDE849’s early partial responses in heavily pretreated small cell lung cancer could sharpen attention on H2 2026 readouts, but they do not remove the core risks around clinical execution, unprofitability and a rich valuation on sales. With the share price already up strongly over 12 months, this DLL3/PARG news feels additive to the thesis rather than thesis-defining, while also slightly increasing dependence on successful oncology data over the next couple of years. However, one key execution risk in this crowded oncology space is easy to overlook.\n\nIDEAYA Biosciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesIDYA 1-Year Stock Price Chart The Simply Wall St Community’s three fair value views for IDEAYA range from US$50 to a very large US$617.80, underscoring how differently people size up the story. Set this wide spread against the company’s ongoing losses and reliance on upcoming oncology trial readouts, and you get a sense of how much hinges on the next few clinical catalysts.Explore 3 other fair value estimates on IDEAYA Biosciences - why the stock might be a potential multi-bagger!The Verdict Is YoursDisagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your IDEAYA Biosciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free IDEAYA Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEAYA Biosciences' overall financial health at a glance.Curious About Other Options?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Uncover the next big thing with 31 elite penny stocks that balance risk and reward.Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624660937","isCrawlerRequest":true}